# Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies

> **NCT04743557** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Dynacure**

## Conditions studied

- Centronuclear Myopathy

## Interventions

- **DRUG:** DYN101

## Key facts

- **NCT ID:** NCT04743557
- **Lead sponsor:** Dynacure
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2025-09
- **Final completion:** 2025-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The first Clinical trial with DYN101 (UNITE-CNM) was early terminated. As a consequence, Dynacure decided to not perform this study.
- **Last updated:** 2022-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04743557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04743557, "Early Phase Human Drug Trial to Investigate DYN101 in Participants 2 to 17 Years With Centronuclear Myopathies". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04743557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*